Tenax TherapeuticsTENX
TENX
About: Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Employees: 6
0
Funds holding %
of 7,432 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
13% more funds holding
Funds holding: 23 [Q1] → 26 (+3) [Q2]
3.26% more ownership
Funds ownership: 50.54% [Q1] → 53.8% (+3.26%) [Q2]
1% less capital invested
Capital invested by funds: $13.1M [Q1] → $12.9M (-$184K) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$14
134%
upside
Avg. target
$14
134%
upside
High target
$14
134%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Seamus Fernandez | 134%upside $14 | Buy Maintained | 14 Aug 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026
Neutral
GlobeNewsWire
3 months ago
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026
Positive
Seeking Alpha
4 months ago
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts
Tenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-modifying therapy for PH-HFpEF, with prior phase 2 success in improving exercise capacity. The company raised $25 million in March 2025, ensuring sufficient funding through 2027 to meet clinical milestones.
Neutral
GlobeNewsWire
4 months ago
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025.
Neutral
GlobeNewsWire
5 months ago
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027
Neutral
GlobeNewsWire
5 months ago
Tenax Therapeutics Announces $25 Million Private Placement
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting placement agent fees and other private placement expenses.
Neutral
GlobeNewsWire
5 months ago
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025
Neutral
GlobeNewsWire
5 months ago
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference, which is taking place from March 10-12, 2025, in Miami, FL.
Neutral
GlobeNewsWire
6 months ago
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference, which is taking place from February 5-6, 2025, in New York, NY.
Neutral
Seeking Alpha
9 months ago
Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript)
Tenax Therapeutics, Inc. (NASDAQ:TENX ) Guggenheim Healthcare Innovation Conference November 13, 2024 1:00 PM ET Company Participants Chris Giordano - President and CEO Stuart Rich - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Seamus Fernandez Good afternoon, everybody. And welcome again to Guggenheim Securities Inaugural Healthcare Innovation Conference.
Charts implemented using Lightweight Charts™